Previous 10 | Next 10 |
home / stock / alpmy / alpmy news
TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract OR33-6 ) at ENDO 2019, the Endocr...
Results from a Phase 3 clinical trial, RELAY , evaluating Eli Lilly's (NYSE: LLY ) CYRAMZA (ramucirumab) for the first-line treatment of patients with EGFR-positive metastatic non-small cell lung cancer (NSCLC) showed a treatment benefit. More news on: Eli Lilly and Company, Roche Hold...
Astellas Pharma ( OTCPK:ALPMY +0.9% ) will collaborate with Woburn, MA-based ReForm Biologics on reformulating its pipeline of biologic therapies to allow for alternative dosing, specifically subcutaneous injection, more efficient manufacturing and longer product life cycles. More ne...
Preliminary data from an open-label Phase 1b/2 clinical trial, KEYNOTE-365 , evaluating Merck's (NYSE: MRK ) Keytruda (pembrolizumab), combined with various agents, in patients with metastatic castration-resistant prostate cancer (mCRPC) showed a treatment effect across three cohorts. Th...
NEW YORK and TOKYO , Feb. 11, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mH...
Japan's Ministry has approved Amgen (NASDAQ: AMGN ) and co-developer UCB's ( OTCPK:UCBJF )( OTCPK:UCBJY ) EVENITY (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture. More news on: Amgen Inc., UCB S.A., UCB S.A. ADR, Healthcare stocks news, Read more ...
Jerusalem-based Anchiano Therapeutics ( OTC:BCNLF ) has filed for an initial public offering of American Depositary Shares. More news on: Anchiano Therapeutics Ltd., Sesen Bio, Inc., Telesta Therapeutics, Inc., Healthcare stocks news, IPO News, Read more ...
Pfizer ( PFE -0.6% ) and U.S. commercialization partner Astellas Pharma ( OTCPK:ALPMF )( OTCPK:ALPMY ) announce positive results from a Phase 3 clinical trial, ARCHES , evaluating XTANDI (enzalutamide) plus androgen deprivation therapy in men with metastatic hormone-sensitive prost...
TOKYO and NEW YORK , Dec. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI ® (enzalutamide) plus androgen deprivation therap...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer PR Newswire - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted...
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - If approved, enfortumab vedotin in combination with pembrolizumab ...
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...